TEVA May 2024 15.500 call
| Previous close | 0.8100 |
| Open | 1.2000 |
| Bid | 1.1900 |
| Ask | 1.4500 |
| Strike | 15.50 |
| Expiry date | 2024-05-17 |
| Day's range | 1.1700 - 1.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.14k |
ZacksShould Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
ZacksTEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up
TEVA reports mixed first-quarter results, missing estimates for earnings but beating the same for sales. It announces promising data from a phase III study on schizophrenia candidate, olanzapine.
Insider MonkeyTeva Pharmaceutical Industries Limited (NYSE:TEVA) Q1 2024 Earnings Call Transcript
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q1 2024 Earnings Call Transcript May 8, 2024 Teva Pharmaceutical Industries Limited misses on earnings expectations. Reported EPS is $-0.12161 EPS, expectations were $0.51. Teva Pharmaceutical Industries Limited isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). […]
